FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Stage III dMMR Colon Cancer
The U.S. Food and Drug Administration (FDA) has approved Roche-owned Genentech’s Tecentriq (atezolizumab) as an adjuvant treatment for patients with Stage III mismatch repair deficient (dMMR) colon cancer in adults and children aged two years or older. This new indication expands the use of Tecentriq, which is already approved for several other cancers. The approval follows clinical trials demonstrating its efficacy in preventing recurrence after surgery by targeting tumors that lack proper DNA repair mechanisms. The decision highlights growing interest in immunotherapy as a treatment option for specific genetic subtypes of cancer and may influence prescribing patterns among oncologists treating dMMR colon cancer patients.
Tickers: $RHHBY
Topics: cancer_treatment pharmaceuticals